Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers
- Conditions
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT04969497
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT04066023
- Locations
- 🇺🇸
KI Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸Jefferson Headache Center, Philadelphia, Pennsylvania, United States
🇺🇸Atlanta Headache Specialists, Atlanta, Georgia, United States
A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers
- Conditions
- Interventions
- Drug: M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches)Drug: M207 3.8 mg "MACAP" (two 1.9 mg patches made on a "MACAP" coater, foil cups)Drug: M207 3.8 mg "MiniMac" (two 1.9 mg patches made on a "MiniMac" coater, foil cupsDrug: Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT03978403
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers
- Conditions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT03708744
- Locations
- 🇺🇸
Hill Top Research, Inc., Neptune, New Jersey, United States
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 342
- Registration Number
- NCT03282227
- Locations
- 🇺🇸
Clinvest Research, Springfield, Missouri, United States
🇺🇸University of Texas Southwestern Medical Center - Neurology Clinic, Dallas, Texas, United States
🇺🇸Primary Care Associates/Radiant Research, Anderson, South Carolina, United States
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 365
- Registration Number
- NCT02745392
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Novex Medical Research, New Bedford, Massachusetts, United States
🇺🇸Clinvest/A Division of Banyan Group Inc., Springfield, Missouri, United States
A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2016-08-23
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT02478879
- Locations
- 🇺🇸
Covance Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States
Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia
- Conditions
- Interventions
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT02459938
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 165
- Registration Number
- NCT00489918